Publication:
Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile

Simple item page
dc.contributor.authorAguilera, Ximena
dc.contributor.authorGonzález, Claudia
dc.contributor.authorApablaza, Mauricio
dc.contributor.authorRubilar, Paola
dc.contributor.authorIcaza, Gloria
dc.contributor.authorRamírez, Muriel
dc.contributor.authorPérez, Claudia
dc.contributor.authorCortes, Lina
dc.contributor.authorNúñez, Loreto
dc.contributor.authorQuezada, Rubén
dc.contributor.authorCastillo, Carla
dc.contributor.authorCorrea, Juan
dc.contributor.authorSaid, Macarena
dc.contributor.authorHormazábal, Juan
dc.contributor.authorVial, Cecilia
dc.contributor.authorVial, Pablo
dc.date.accessioned2023-04-27T20:12:02Z
dc.date.available2023-04-27T20:12:02Z
dc.date.issued2022
dc.description.abstractChile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7-93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8-2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.
dc.description.versionVersión Publicada
dc.identifier.citationAguilera X, González C, Apablaza M, Rubilar P, Icaza G, Ramírez-Santana M, Pérez C, Cortes LJ, Núñez-Franz L, Quezada-Gaete R, Castillo-Laborde C, Correa J, Said M, Hormazábal J, Vial C, Vial P. Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile. Vaccines (Basel). 2022 Jun 23;10(7):1002. doi: 10.3390/vaccines10071002
dc.identifier.doihttps://doi.org/10.3390/vaccines10071002
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7423
dc.language.isoen
dc.subjectCOVID-19
dc.subjectVaccines
dc.subjectSinovac Coronavac
dc.subjectBNT162b2
dc.subjectAZD1222
dc.subjectELISA
dc.subjectCross-sectional
dc.titleImmunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceVaccines
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2. Immunization and SARS-CoV-2 Antibody Seroprevalence in a.pdf
Size:
588.38 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud
Artículos Gobierno

Implementado por OpenGeek Services